CVE-2020-27256 describes a hard-coded physician PIN vulnerability in SOOIL Developments Co., Ltd Diabecare RS, AnyDana-i, and AnyDana-A insulin pumps. This flaw allows an attacker with physical access to the device to bypass authentication and modify critical insulin therapy settings. With a CVSS score of 6.8 (Medium), the vulnerability has a high impact on confidentiality, integrity, and availability, requiring physical proximity but no user interaction or complex attack steps. There is currently no evidence of active exploitation, publicly available exploit code (Metasploit, Nuclei, ExploitDB), or significant community discussion or media coverage surrounding this CVE.
| Vendor | Product | Version(s) | CPE |
|---|---|---|---|
< 3.0CPE matchmatch criteria | cpe:2.3:o:sooil:anydana-a_firmware:*:*:*:*:*:*:*:* | ||
< 3.0CPE matchmatch criteria | cpe:2.3:o:sooil:anydana-i_firmware:*:*:*:*:*:*:*:* | ||
< 3.0CPE matchmatch criteria | cpe:2.3:o:sooil:diabecare_rs_firmware:*:*:*:*:*:*:*:* |
CVSS version used by this source: 3.1
CVSS:3.1/AV:P/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
The average CVE in this peer group has 0.0 Twitter, 0.1 Reddit, 0.1 Bluesky, 0.0 Mastodon, and 0.1 GitHub mentions.
No media coverage found for this CVE.
The average CVE in this peer group has 0.2 InfoSec Media, 0.0 Vendor Blog, and 0.0 Security Researcher mentions.
Remediation records are not available for this CVE.